(Reuters) - Reckitt Benckiser (RB.L) plans to spin off its heroin-addiction treatment in the next 12 months as sales slide under pressure from rival copycat versions of the drug.
Sales of Suboxone have slumped and Reckitt has two new pharmaceutical projects that could diversify revenue and boost the unit’s market valuation.
The British company put Suboxone under strategic review in October and in April said it was leaning towards spinning off the business rather than a private sale.
Help employers find you! Check out all the jobs and post your resume.
